Menu
// R&D pipeline
Oncolytic mRNA & TME modifying mRNA
eTheRNA is developing mRNA-based products mimicking the action of oncolytic viruses. A mRNA-based approach has several advantages over oncolytic viruses:
- It's easier to regulate the mode of action of an mRNA-based product
- Side effects are expected to be less severe
- No viral antigens or anti-vector immunity
A single construct or a mix of naked or packaged mRNA is delivered directly into the tumour site giving direct access to the effector site of the therapy. This modality offers opportunities to develop products with cell-lytic, tumour microenvironment modulating mRNA
Preliminary in vitro and ex vivo experiments have provided promising anti-tumour responses in both the treated and untreated tumours suggesting a systemic response from a loco-regional delivery.
Menu
Galileilaan 19, 2845 Niel, Belgium
Our Address
Our Mailbox
+32 3 369 17 40
Our Phone
Menu
© 2020 Etherna | Studio Hanswijk